Research programme: NeuGene antisense compounds - Sarepta Therapeutics

Drug Profile

Research programme: NeuGene antisense compounds - Sarepta Therapeutics

Alternative Names: AVI 4179; AVI 4451; AVI 4XXX; NeuBiotics

Latest Information Update: 18 Apr 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AVI BioPharma
  • Developer Sarepta Therapeutics
  • Class Antisense oligonucleotides; Morpholines
  • Mechanism of Action Genetic transcription inhibitors; HMG-CoA reductase inhibitors; Intercellular adhesion molecule 1 antagonists; Intercellular adhesion molecule 3 antagonists; NF-kappa B inhibitors; Nitric oxide synthase inhibitors; Proto-oncogene protein c-myc modulators; RNA interference; RNA synthesis inhibitors; Testosterone congener inhibitors; Transforming growth factor beta stimulants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Anthrax; Bacterial infections; Ricin poisoning
  • Discontinued Coronary artery restenosis; Hypercholesterolaemia; Immunological disorders; Inflammation; Multiple sclerosis; Prostate cancer; Stem cell mobilisation

Most Recent Events

  • 18 Apr 2013 No development reported - Preclinical for Anthrax in USA (Parenteral)
  • 18 Apr 2013 No development reported - Preclinical for Bacterial infections in USA (Parenteral)
  • 12 Jul 2012 AVI BioPharma is now called Sarepta Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top